ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS SECRETS

In Segment C, individuals will obtain ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment until eventually ailment progression or maybe the participants are unable to tolerate the study drugs.after which you can advertise H3K27Ac at this location. Chromatin hyperacetylation cou